The bipartisan legislation would prohibit federal contracts, loans or grants to any Chinese “biotechnology company of concern.” That would apply to companies with research agreements with the National Institutes of Health or sales to the Department of Veterans Affairs or the Department of Defense, including TRICARE.
Because reimbursements are not considered a federal contract, the updated legislation would not affect Medicare and Medicaid payments, according to staff on the 网页链接{House Oversight and Accountability Committee}, which will be voting on the bill.

中金跌不下去了，不会探底了，最多回调震荡一下，比你T出的价格高

游总为啥这么看好中金公司？

投票大概率过 就看是否包括医保这部分